All news
DIPLOMA Trial: Minimally Invasive Surgery is an Effective Treatment Option for Early-Stage Pancreatic Cancer
18 July 2023A notable study, DIPLOMA, led by Abu Hilal, M.D., Ph.D., of the Istituto Ospedaliero Fondazione Poliambulanza in Brescia, Italy, involved a large c...
Personalized mRNA Pancreatic Cancer Vaccine Shows Promising Results in Small Trial
18 July 2023Messenger RNA (mRNA) vaccines – famous for preventing symptomatic infection of COVID-19—are starting to show some promise against pancreati...
ESMO Study Confirms Precision Oncology Remains Largely Inaccessible to European Cancer Patients
18 July 2023As a European umbrella organisation, DiCE is vocal in addressing the disparities associated with cancer patients’ access to precision medicin...
Primary and Updated Analyses for DESTINY-Gastric02 Study: Trastuzumab Deruxtecan Continues to Demonstrate Benefit in Metastatic Gastric and Gastro-oesophageal Cancer
17 July 2023Human Epidermal Growth receptor 2 (HER2) is a protein involved in normal cell growth, found in small amounts in almost all human cells, including s...
RWE Research in mCRC
17 July 2023In a recent article published in the Future Oncology, Patient Advocates and DiCE CEO Zorana Maravic explored and enhanced the understanding of the ...
Manifesto for a Healthier Europe
17 July 2023DiCE, together with the EU Health Coalition, urges future EU leaders to prioritise health and life sciences. Ahead of next year’s European el...
EU Commission Approval of Tibsovo® (Ivosidenib) in IDH1-mutated Cholangiocarcinoma
17 July 2023The European Commission approved the use of Tibsovo® (Ivosidenib) as monotherapy for the treatment of locally advanced or metastatic cholangiocarc...
Collaboration with COR2ED – HCC CONNECT
18 June 2023DiCE is pleased to collaborate with HCC CONNECT. HCC CONNECT is an international group of experts in hepatocellular carcinoma (HCC).
...
Liver Cancer Index – Data Gaps
14 June 2023DiCE has started disseminating a survey this spring among clinicians, public health experts, and patient advocates to help to sketch the landscape ...
DiCE at the WECAN Retreat 2023
26 May 2023DiCE attended the Workgroup of European Cancer Patient Advocacy Networks (WECAN) retreat on the 20 and 21 April in Frankfurt (Germany). WECAN is a ...
